Search Results - "James, Sonya"

Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo by Roghanian, Ali, Teige, Ingrid, Mårtensson, Linda, Cox, Kerry L., Kovacek, Mathilda, Ljungars, Anne, Mattson, Jenny, Sundberg, Annika, Vaughan, Andrew T., Shah, Vallari, Smyth, Neil R., Sheth, Bhavwanti, Chan, H.T. Claude, Li, Zhan-Chun, Williams, Emily L., Manfredi, Giusi, Oldham, Robert J., Mockridge, C. Ian, James, Sonya A., Dahal, Lekh N., Hussain, Khiyam, Nilsson, Björn, Verbeek, J. Sjef, Juliusson, Gunnar, Hansson, Markus, Jerkeman, Mats, Johnson, Peter W.M., Davies, Andrew, Beers, Stephen A., Glennie, Martin J., Frendéus, Björn, Cragg, Mark S.

“…Therapeutic antibodies have transformed cancer therapy, unlocking mechanisms of action by engaging the immune system. Unfortunately, cures rarely occur and…”
Get full text

Activation of GABA(A) receptors inhibits T cell proliferation by Sparrow, Emma L, James, Sonya, Hussain, Khiyam, Beers, Stephen A, Cragg, Mark S, Bogdanov, Yury D

“…The major sites for fast synaptic inhibition in the central nervous system (CNS) are ion channels activated by γ-aminobutyric acid (GABA). These receptors are…”
Get full text

Immune characterization of pre-clinical murine models of neuroblastoma by Webb, Emily R., Lanati, Silvia, Wareham, Carol, Easton, Alistair, Dunn, Stuart N., Inzhelevskaya, Tatyana, Sadler, Freja M., James, Sonya, Ashton-Key, Margaret, Cragg, Mark S., Beers, Stephen A., Gray, Juliet C.

“…Immunotherapy offers a potentially less toxic, more tumor-specific treatment for neuroblastoma than conventional cytotoxic therapies. Accurate and reproducible…”
Get full text

HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy by Hussain, Khiyam, Liu, Rena, Smith, Rosanna C G, Müller, Kri T J, Ghorbani, Mohammadmersad, Macari, Sofia, Cleary, Kirstie L S, Oldham, Robert J, Foxall, Russell B, James, Sonya, Booth, Steven G, Murray, Tom, Dahal, Lekh N, Hargreaves, Chantal E, Kemp, Robert S, Longley, Jemma, Douglas, James, Markham, Hannah, Chee, Serena J, Stopforth, Richard J, Roghanian, Ali, Carter, Matthew J, Ottensmeier, Christian H, Frendéus, Bjorn, Cutress, Ramsey I, French, Ruth R, Glennie, Martin J, Strefford, Jonathan C, Thirdborough, Stephen M, Beers, Stephen A, Cragg, Mark S

“…Hypoxia is a hallmark of the tumor microenvironment (TME) and in addition to altering metabolism in cancer cells, it transforms tumor-associated stromal cells…”
Get full text

TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity by Yu, Xiaojie, James, Sonya, Felce, James H., Kellermayer, Blanka, Johnston, David A., Chan, H. T. Claude, Penfold, Christine A., Kim, Jinny, Inzhelevskaya, Tatyana, Mockridge, C. Ian, Watanabe, Yasunori, Crispin, Max, French, Ruth R., Duriez, Patrick J., Douglas, Leon R., Glennie, Martin J., Cragg, Mark S.

“…Monoclonal antibodies (mAb) and natural ligands targeting costimulatory tumor necrosis factor receptors (TNFR) exhibit a wide range of agonistic activities and…”
Get full text

Cyclophosphamide depletes tumor infiltrating T regulatory cells and combined with anti-PD-1 therapy improves survival in murine neuroblastoma by Webb, Emily R., Moreno-Vicente, Julia, Easton, Alistair, Lanati, Silvia, Taylor, Martin, James, Sonya, Williams, Emily L., English, Vikki, Penfold, Chris, Beers, Stephen A., Gray, Juliet C.

“…The outcome for children with high-risk neuroblastoma is poor despite intensive multi-modal treatment protocols. Toxicity from current treatments is…”
Get full text

FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion by Oldham, Robert J, Mockridge, C Ian, James, Sonya, Duriez, Patrick J, Chan, H T Claude, Cox, Kerry L, Pitic, Vicentiu A, Glennie, Martin J, Cragg, Mark S

“…BackgroundImmune compromised mice are increasingly used for the preclinical development of monoclonal antibodies (mAb). Most common are non-obese diabetic…”
Get full text

On-target IgG hexamerisation driven by a C-terminal IgM tail-piece fusion variant confers augmented complement activation by Sopp, Joshua M., Peters, Shirley J., Rowley, Tania F., Oldham, Robert J., James, Sonya, Mockridge, Ian, French, Ruth R., Turner, Alison, Beers, Stephen A., Humphreys, David P., Cragg, Mark S.

“…The majority of depleting monoclonal antibody (mAb) drugs elicit responses via Fc-FcγR and Fc-C1q interactions. Optimal C1q interaction is achieved through…”
Get full text

Reducing affinity as a strategy to boost immunomodulatory antibody agonism by Yu, Xiaojie, Orr, Christian M., Chan, H. T. Claude, James, Sonya, Penfold, Christine A., Kim, Jinny, Inzhelevskaya, Tatyana, Mockridge, C. Ian, Cox, Kerry L., Essex, Jonathan W., Tews, Ivo, Glennie, Martin J., Cragg, Mark S.

“…Antibody responses during infection and vaccination typically undergo affinity maturation to achieve high-affinity binding for efficient neutralization of…”
Get full text

Activation of GABA by Sparrow, Emma L, James, Sonya, Hussain, Khiyam, Beers, Stephen A, Cragg, Mark S, Bogdanov, Yury D

“…Background The major sites for fast synaptic inhibition in the central nervous system (CNS) are ion channels activated by [gamma]-aminobutyric acid (GABA)…”
Get full text

Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function by Buchan, Sarah L., Dou, Lang, Remer, Marcus, Booth, Steven G., Dunn, Stuart N., Lai, Chester, Semmrich, Monika, Teige, Ingrid, Mårtensson, Linda, Penfold, Christine A., Chan, H.T. Claude, Willoughby, Jane E., Mockridge, C. Ian, Dahal, Lekh N., Cleary, Kirstie L.S., James, Sonya, Rogel, Anne, Kannisto, Päivi, Jernetz, Mats, Williams, Emily L., Healy, Eugene, Verbeek, J. Sjef, Johnson, Peter W.M., Frendéus, Björn, Cragg, Mark S., Glennie, Martin J., Gray, Juliet C., Al-Shamkhani, Aymen, Beers, Stephen A.

“…The costimulatory receptor 4-1BB is expressed on activated immune cells, including activated T cells. Antibodies targeting 4-1BB enhance the proliferation and…”
Get full text

ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance by Mellone, Massimiliano, Piotrowska, Klaudia, Venturi, Giulia, James, Lija, Bzura, Aleksandra, Lopez, Maria A, James, Sonya, Wang, Chuan, Ellis, Matthew J, Hanley, Christopher J, Buckingham, Josephine F, Cox, Kerry L, Hughes, Gareth, Valge-Archer, Viia, King, Emma V, Beers, Stephen A, Jaquet, Vincent, Jones, George D D, Savelyeva, Natalia, Sayan, Emre, Parsons, Jason L, Durant, Stephen, Thomas, Gareth J

“…Myofibroblastic cancer-associated fibroblast (myoCAF)-rich tumors generally contain few T cells and respond poorly to immune-checkpoint blockade. Although…”
Get full text

Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment by Turaj, Anna H., Hussain, Khiyam, Cox, Kerry L., Rose-Zerilli, Matthew J.J., Testa, James, Dahal, Lekh N., Chan, H.T. Claude, James, Sonya, Field, Vikki L., Carter, Matthew J., Kim, Hyung J., West, Jonathan J., Thomas, Lawrence J., He, Li-Zhen, Keler, Tibor, Johnson, Peter W.M., Al-Shamkhani, Aymen, Thirdborough, Stephen M., Beers, Stephen A., Cragg, Mark S., Glennie, Martin J., Lim, Sean H.

“…Monoclonal antibodies (mAbs) can destroy tumors by recruiting effectors such as myeloid cells, or targeting immunomodulatory receptors to promote cytotoxic…”
Get full text

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation by Beers, Stephen A., Chan, Claude H.T., James, Sonya, French, Ruth R., Attfield, Kathrine E., Brennan, Claire M., Ahuja, Anupama, Shlomchik, Mark J., Cragg, Mark S., Glennie, Martin J.

“…Anti-CD20 monoclonal antibodies (mAbs) are classified into type I (rituximab-like) or type II (tositumomab-like) based on their ability to redistribute CD20…”
Get full text

FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms by Simpson, Alexander P., Roghanian, Ali, Oldham, Robert J., Chan, H.T. Claude, Penfold, Christine A., Kim, Hyung J., Inzhelevskaya, Tatyana, Mockridge, C. Ian, Cox, Kerry L., Bogdanov, Yury D., James, Sonya, Tutt, Alison L., Rycroft, Daniel, Morley, Peter, Dahal, Lekh N., Teige, Ingrid, Frendeus, Björn, Beers, Stephen A., Cragg, Mark S.

“…Many therapeutic antibodies deplete target cells and elicit immunotherapy by engaging activating Fc gamma receptors (FcγRs) on host effector cells. These…”
Get full text

Immunomodulatory Monoclonal Antibodies Combined with Peptide Vaccination Provide Potent Immunotherapy in an Aggressive Murine Neuroblastoma Model by WILLIAMS, Emily L, DUNN, Stuart N, JAMES, Sonya, JOHNSON, Peter W, CRAGG, Mark S, GLENNIE, Martin J, GRAY, Juliet C

“…Neuroblastoma is one of the commonest extracranial tumors of childhood. The majority of patients present with metastatic disease for which outcome remains…”
Get full text

Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors by Tutt, Alison L, James, Sonya, Laversin, Stéphanie A, Tipton, Thomas R W, Ashton-Key, Margaret, French, Ruth R, Hussain, Khiyam, Vaughan, Andrew T, Dou, Lang, Earley, Alexander, Dahal, Lekh N, Lu, Chen, Dunscombe, Melanie, Chan, H T Claude, Penfold, Christine A, Kim, Jinny H, Potter, Elizabeth A, Mockridge, C Ian, Roghanian, Ali, Oldham, Robert J, Cox, Kerry L, Lim, Sean H, Teige, Ingrid, Frendéus, Bjorn, Glennie, Martin J, Beers, Stephen A, Cragg, Mark S

“…FcγRs are key regulators of the immune response, capable of binding to the Fc portion of IgG Abs and manipulating the behavior of numerous cell types. Through…”
Get full text

HIF activation enhances Fc[gamma]RIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy by Müller, Kri T. J, French, Ruth R, Beers, Stephen A, Carter, Matthew J, Oldham, Robert J, Foxall, Russell B, Smith, Rosanna C. G, Cragg, Mark S, Liu, Rena, Cleary, Kirstie L. S, Roghanian, Ali, Murray, Tom, Douglas, James, James, Sonya, Stopforth, Richard J, Ottensmeier, Christian H, Hargreaves, Chantal E, Booth, Steven G, Dahal, Lekh N, Markham, Hannah, Cutress, Ramsey I, Ghorbani, Mohammadmersad, Chee, Serena J, Kemp, Robert S, Longley, Jemma, Macari, Sofia, Strefford, Jonathan C, Glennie, Martin J, Hussain, Khiyam, Frendéus, Bjorn, Thirdborough, Stephen M

“…Background Hypoxia is a hallmark of the tumor microenvironment (TME) and in addition to altering metabolism in cancer cells, it transforms tumor-associated…”
Get full text

Anti-CD27 Enhances Lymphoma Immunotherapy through Profound Myeloid Cell Recruitment by Turaj, Anna H, Field, Vikki L, Chan, Claude H.T., Penfold, Christine A., Kim, Jinny H., James, Sonya, Cox, Kerry L, Keler, Tibor, Johnson, Peter M, Al-Shamkhani, Aymen, Beers, Stephen A, Glennie, Martin J., Cragg, Mark S, Lim, Sean H

“…Direct-targeting monoclonal antibodies (mAb) such as anti-CD20 mAb are thought to elicit their anti-tumor function through antibody-dependent cellular…”
Get full text

CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses by Castro, Fernanda V.V, Tutt, Alison L, White, Ann L, Teeling, Jessica L, James, Sonya, French, Ruth R, Glennie, Martin J

“…The magnitude and quality of T cell responses generated when Ag is targeted to receptors on DC is influenced by both the specific receptor targeted and its…”
Get full text